MUC5AC and biliary tract neoplasm: We believe the ultimate delineation of the hPAM4 epitope may lead to its exploration as a candidate for vaccine development, while providing valuable insight for diagnosis and treatment of MUC5AC-expressing cancers, such as biliary tract cancer [47], colorectal cancer [48], and gastric cancer [49], in addition to PDAC.